Compare EDD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDD | ATYR |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.5M | 79.2M |
| IPO Year | N/A | 2015 |
| Metric | EDD | ATYR |
|---|---|---|
| Price | $5.57 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 254.3K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.22 | $0.64 |
| 52 Week High | $4.95 | $7.29 |
| Indicator | EDD | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 41.75 |
| Support Level | $5.41 | $0.70 |
| Resistance Level | $5.55 | $0.85 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 58.62 | 19.29 |
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.